Clarity Pharmaceuticals Ltd (CU6)

Snapshot

CU6's Principal Activity is the clarity is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Directors & Management

Name	Title	Since	Bio
Mr Robert Bain Thomas	Non-Executive Director	Aug 2021	Mr Robert Bain Thomas Non-Executive Director Mr Thomas has a background in financial services and capital markets and has experience in mergers & acquisitions and capital markets including advising on the IPOs of the Commonwealth Bank of Australia and Qantas. Mr Thomas is the former CEO of County NatWest Securities and the former CEO (and then Chairman) of Citi Corporate and Investment Bank Australasia. Mr Thomas has also held the position of Chairman at Australian Wealth Management Ltd (ultimately IOOF Ltd), TAL (Australia's largest life insurance company) and the previously ASX-listed company HeartWare International Inc. Mr Thomas is the Chairman of AusBio Ltd, Grahger Retail Securities Pty Ltd and ASX-listed Starpharma Holdings Limited, and is a non-executive director of Biotron Limited and O'Connell Street Associates. He is a past non-executive director of Reva Medical Inc. and Virgin Australia. He is also served as chair of Risk Committee of CU6.
Dr Colin David Biggin	Chief Executive Officer,Managing Director	Oct 2019	Dr Colin David Biggin Chief Executive Officer,Managing Director Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo (radium-223 dichloride) for metastatic prostate cancer, which was approved by the FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.
Dr Charles Gillies O'Bryan-Tear	Non-Executive Director	Apr 2019	Dr Charles Gillies O'Bryan-Tear Non-Executive Director Dr O'Bryan-Tear has over 30 years of experience in the pharmaceutical industry in clinical development, medical management and commercial roles. He has held senior leadership roles in large and small pharmaceutical and biotech companies in the US and Europe and has been involved in multiple product approvals. He was previously the Chief Medical Officer of Algeta ASA. Dr O'Bryan-Tear has been an adviser to several US and European biotech companies and is a member of the Scientific Advisory Boards of Audentes, Inc. (US) and Fusion Pharmaceuticals Inc. (Canada).
Dr Thomas Ramdahl	Non-Executive Director	Mar 2019	Dr Thomas Ramdahl Non-Executive Director Dr Ramdahl is a pharmaceutical executive with over 20 years of clinical and development experience. In 2001, he became President and the first CEO of Algeta ASA. When Dr Ramdahl joined Algeta, he was one of six employees and he was involved in serving in several senior positions within the company through to and post the acquisition of Algeta by Bayer AG in 2014. Dr Ramdahl has authored more than 40 publications and is a co-inventor of several patents. Dr Ramdahl currently serves as Chairman of Precirix (Belgium) and AppSens AS (Norway).
Dr Christopher Graham Roberts	Non-Executive Director	Mar 2016	Dr Christopher Graham Roberts Non-Executive Director Dr Roberts has over 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career. Dr Roberts was previously the CEO of ASX-listed company Cochlear Limited and Chairman of ASX-listed company Sirtex Medical Ltd. Dr Roberts was also Executive VicePresident and a director of the dual-listed (ASX and NYSE) company ResMed Inc., a global sleep disorder treatment company. Dr Roberts is Chairman of the ASX-listed company Oncosil Ltd. He is also served as member of Risk Committee of CU6.
Dr Alan John Taylor	Executive Chairman,Executive Director	Nov 2013	Dr Alan John Taylor Executive Chairman,Executive Director Dr Taylor has approximately 15 years of investment banking experience focused mainly on the life sciences sector, and also has experience in capital raisings, mergers and acquisitions, and general corporate advisory. Prior to joining Clarity, Dr Taylor was an Executive Director of Inteq Limited, a boutique Australian investment bank.
Ms Rosanne Elizabeth Robinson	Non-Executive Director	Oct 2010	Ms Rosanne Elizabeth Robinson Non-Executive Director Ms Robinson has experience in the nuclear field and has over 25 years of experience in both governance and management roles in public and private companies and government. Ms Robinson is the General Manager of Business Development at Australian Nuclear Science and Technology Organization. Ms Robinson also has experience of the nuclear medicine industry and knowledge of most recent changes in the sector. She is also served as member of Risk Committee of CU6.
Mr Robert Cochrane Vickery	Chief Financial Officer,Company Secretary	N/A

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Robert Thomas	25/08/2021	550,000	475,000	N/A	N/A
Colin Biggin	01/10/2019	419,100	N/A	5,600,000	N/A
Charles O'Bryan-Tear	03/04/2019	N/A	N/A	900,000	N/A
Thomas Ramdahl	26/03/2019	N/A	N/A	600,000	N/A
Christopher Roberts	24/03/2016	N/A	17,911,280	200,000	N/A
Alan Taylor	28/11/2013	N/A	14,066,660	2,800,000	N/A
Rosanne Robinson	19/10/2010	N/A	N/A	200,000	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
TM Ventures Pty Ltd	18,788,460	7.34%
Cabbit Pty Ltd	17,911,280	6.99%
Genesiscare Ventures	15,362,700	6.00%
A.C.N. 136 437 913 Pty Ltd	13,266,660	5.18%
Charles Waite Morgan	12,330,220	4.81%
HSBC Custody Nominees (Australia) Limited (i)	10,669,568	4.17%
National Nominees Limited	8,020,161	3.13%
Boorris Pty Ltd	7,815,800	3.05%
Vantres Pty Ltd	7,487,340	2.92%
Yarrawah Pty Ltd	6,752,859	2.64%
Firetrail Investments Pty Ltd	6,000,000	2.34%
Moore Family Nominee Pty Ltd	5,800,000	2.26%
Hat Investments Atf Hunter Angels Trust No 1	5,599,180	2.19%
Smarter Capital Pty Ltd	5,500,000	2.15%
Citicorp Nominees Pty Limited	5,187,176	2.03%
Kylaco Pty Ltd	3,896,280	1.52%
UBS Nominees Pty Ltd	3,648,150	1.42%
Australian Nuclear Science & Technology Organisation	3,599,920	1.41%
HSBC Custody Nominees (Australia) Limited (ii)	3,571,429	1.39%
CS Third Nominees Pty Limited	3,500,000	1.37%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
No Financial Year End data available

CU6 Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.